We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

92 hedge funds and large institutions have $227M invested in Eiger BioPharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more call options, than puts

Call options by funds: $2.22M | Put options by funds: $905K

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

21% more capital invested

Capital invested by funds: $188M → $227M (+$39M)

1% more funds holding

Funds holding: 91 → 92 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
92
Holders Change
+1
Holders Change %
+1.1%
% of All Funds
1.58%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
12
Increased
36
Reduced
25
Closed
11
Calls
$2.22M
Puts
$905K
Net Calls
+$1.32M
Net Calls Change
+$652K

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$4.42M
2
6CM
683 Capital Management
New York
+$3.81M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$3.37M
4
Ameriprise
Ameriprise
Minnesota
+$3.27M
5
CA
CHI Advisors
New York
+$2.17M

Top Sellers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
-$5.14M
2
Morgan Stanley
Morgan Stanley
New York
-$3.32M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.27M
4
KCM
Knoll Capital Management
Florida
-$887K
5
TI
Telemetry Investments
New York
-$815K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$1.52M -$452K -1,839 -21%
Prudential Financial
27
Prudential Financial
New Jersey
$1.49M +$1.12M +4,548 +222%
Osaic Holdings
28
Osaic Holdings
Arizona
$1.4M +$349K +1,420 +30%
TI
29
Telemetry Investments
New York
$1.34M -$815K -3,314 -36%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.04M +$169K +689 +18%
DS
31
DRW Securities
Illinois
$906K – – –
CC
32
Caxton Corporation
New Jersey
$880K – – –
JP Morgan Chase
33
JP Morgan Chase
New York
$862K -$1.97K -8 -0.2%
Charles Schwab
34
Charles Schwab
California
$818K +$16.7K +68 +2%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$770K -$1.27M -5,153 -60%
N
36
Nuveen
North Carolina
$768K +$18.9K +77 +2%
Skandinaviska Enskilda Banken (SEB)
37
Skandinaviska Enskilda Banken (SEB)
Sweden
$762K – – –
WMSA
38
Weiss Multi-Strategy Advisers
New York
$753K -$334K -1,359 -29%
Citadel Advisors
39
Citadel Advisors
Florida
$595K +$648K +2,636 New
KCM
40
Knoll Capital Management
Florida
$586K -$887K -3,609 -16%
TAM
41
Tocqueville Asset Management
New York
$539K +$73.7K +300 +14%
SPC
42
Sigma Planning Corp
Michigan
$482K +$2.21K +9 +0.4%
PAM
43
Panagora Asset Management
Massachusetts
$447K +$3.93K +16 +0.8%
CC
44
Carlson Capital
Texas
$414K -$82.1K -334 -15%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$409K +$27.3K +111 +7%
Two Sigma Investments
46
Two Sigma Investments
New York
$381K -$92.9K -378 -18%
Connor, Clark & Lunn Investment Management (CC&L)
47
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$366K +$281K +1,143 +239%
CWM
48
Curi Wealth Management
North Carolina
$339K +$369K +1,500 New
AllianceBernstein
49
AllianceBernstein
Tennessee
$271K +$22.9K +93 +8%
ZCA
50
Zeke Capital Advisors
Pennsylvania
$267K – – –
1
2
3 4 5

EIGR Hedge Fund Activity: Q3 2022 in Review

92 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2022, worth a combined $227M — up 21% from $188M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new EIGR positions and 11 closed out — a net gain of 1 holder — while 36 added to existing stakes and 25 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $4.42M. The largest seller was Soleus Capital Management, cutting an estimated $5.14M.

  • 92 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2022, up from 91 in Q2 2022.
  • Funds reported $227M of Eiger BioPharmaceuticals, Inc. stock for Q3 2022, up 21% quarter-over-quarter.
  • 12 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2022 and 11 closed out, a net change of +1 holder.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2022 was Baker Bros. Advisors, an estimated $4.42M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2022 was Soleus Capital Management, an estimated $5.14M sold.

Based on aggregated 13F filings for Q3 2022.